ID

45925

Beschreibung

Principal Investigator: Francine Garrett-Bakelman, MD, PhD, University of Virginia, Charlottesville, VA, USA; Weill Cornell Medical College, New York, NY, USA MeSH: Acute Myeloid Leukemia https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001027 Acute Myeloid Leukemia (AML) remains a clinical challenge since most patients diagnosed with AML will die from the disease. Some patients harbor treatment-refractory disease and many others relapse with disease that in many cases is resistant to treatments. Our study was designed to understand the molecular basis of disease progression in AML through assessing genomics signatures in patient specimens collected through an international collaboration which assembled samples from 138 AML patients which experienced disease relapse and normal hematopoietic cells (n=15). It is hoped that this resource will help researchers understand mechanisms of disease relapse in AML and contribute to the general pool of data available for analyses for this disease and general research use.

Link

dbGaP study = phs001027

Stichworte

Versionen (1)
  1. 27.02.24 27.02.24 - Simon Heim
Rechteinhaber

Francine Garrett-Bakelman, MD, PhD, University of Virginia, Charlottesville, VA, USA; Weill Cornell Medical College, New York, NY, USA

Hochgeladen am

27. Februar 2024

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

dbGaP phs001027 Epigenomics Studies in Acute Myeloid Leukemia (AML)

Englisch

Eligibility Criteria

6 Formulare  
Inclusion and exclusion criteria
Beschreibung

Inclusion and exclusion criteria

Alias
UMLS CUI [1,1]
C1512693
UMLS CUI [1,2]
C0680251
Inclusion and exclusion criteria for specimens included:
Beschreibung

Inclusion and exclusion criteria for specimens included:

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1512693
UMLS CUI [1,2]
C0680251
UMLS CUI [1,3]
C0370003
Inclusion criteria: patients diagnosed with non-M3 Acute Myeloid Leukemia (AML), who received induction chemotherapy treatment with combination chemotherapy including, but not limited to an anthracycline and cytosine arabinoside, and patients from whom specimens with high blast cell percentages were available from diagnosis and relapse time points. Patient-matched germline specimens were collected in a sub-set of patients, and age-matched controls were obtained from individuals without any known hematological conditions with CD34+ cell enrichment greater than 90%.
Beschreibung

Inclusion criteria: patients diagnosed with non-M3 Acute Myeloid Leukemia (AML), who received induction chemotherapy treatment with combination chemotherapy including, but not limited to an anthracycline and cytosine arabinoside, and patients from whom specimens with high blast cell percentages were available from diagnosis and relapse time points. Patient-matched germline specimens were collected in a sub-set of patients, and age-matched controls were obtained from individuals without any known hematological conditions with CD34+ cell enrichment greater than 90%.

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1512693
UMLS CUI [1,2]
C2735298
UMLS CUI [1,3]
C5206782
UMLS CUI [1,4]
C4272796
UMLS CUI [1,5]
C1521750
UMLS CUI [1,6]
C0282564
UMLS CUI [1,7]
C0604937
UMLS CUI [1,8]
C0587348
UMLS CUI [1,9]
C0470187
UMLS CUI [1,10]
C2707520
UMLS CUI [1,11]
C1442880
UMLS CUI [1,12]
C0011900
UMLS CUI [1,13]
C0035020
UMLS CUI [2,1]
C3845275
UMLS CUI [2,2]
C0150103
UMLS CUI [2,3]
C5192904
UMLS CUI [2,4]
C0001779
UMLS CUI [2,5]
C0686906
UMLS CUI [2,6]
C0018939
UMLS CUI [2,7]
C5205410
Exclusion criteria: patients with M3 AML (Acute Promyelocytic Leukemia), patients who received treatments not including an anthracycline and cytosine arabinoside during induction treatment, patients who relapsed more than five years after the original diagnosis.
Beschreibung

Exclusion criteria: patients with M3 AML (Acute Promyelocytic Leukemia), patients who received treatments not including an anthracycline and cytosine arabinoside during induction treatment, patients who relapsed more than five years after the original diagnosis.

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0680251
UMLS CUI [1,2]
C0023487
UMLS CUI [1,3]
C0087111
UMLS CUI [1,4]
C0282564
UMLS CUI [1,5]
C0604937
UMLS CUI [1,6]
C0857127
UMLS CUI [2,1]
C0205336
UMLS CUI [2,2]
C3843629
UMLS CUI [2,3]
C0332137
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Criteria

6 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
Inclusion and exclusion criteria
C1512693 (UMLS CUI [1,1])
C0680251 (UMLS CUI [1,2])
Inclusion and exclusion criteria for specimens included:
Item
Inclusion and exclusion criteria for specimens included:
boolean
C1512693 (UMLS CUI [1,1])
C0680251 (UMLS CUI [1,2])
C0370003 (UMLS CUI [1,3])
Inclusion criteria: patients diagnosed with non-M3 Acute Myeloid Leukemia (AML), who received induction chemotherapy treatment with combination chemotherapy including, but not limited to an anthracycline and cytosine arabinoside, and patients from whom specimens with high blast cell percentages were available from diagnosis and relapse time points. Patient-matched germline specimens were collected in a sub-set of patients, and age-matched controls were obtained from individuals without any known hematological conditions with CD34+ cell enrichment greater than 90%.
Item
Inclusion criteria: patients diagnosed with non-M3 Acute Myeloid Leukemia (AML), who received induction chemotherapy treatment with combination chemotherapy including, but not limited to an anthracycline and cytosine arabinoside, and patients from whom specimens with high blast cell percentages were available from diagnosis and relapse time points. Patient-matched germline specimens were collected in a sub-set of patients, and age-matched controls were obtained from individuals without any known hematological conditions with CD34+ cell enrichment greater than 90%.
boolean
C1512693 (UMLS CUI [1,1])
C2735298 (UMLS CUI [1,2])
C5206782 (UMLS CUI [1,3])
C4272796 (UMLS CUI [1,4])
C1521750 (UMLS CUI [1,5])
C0282564 (UMLS CUI [1,6])
C0604937 (UMLS CUI [1,7])
C0587348 (UMLS CUI [1,8])
C0470187 (UMLS CUI [1,9])
C2707520 (UMLS CUI [1,10])
C1442880 (UMLS CUI [1,11])
C0011900 (UMLS CUI [1,12])
C0035020 (UMLS CUI [1,13])
C3845275 (UMLS CUI [2,1])
C0150103 (UMLS CUI [2,2])
C5192904 (UMLS CUI [2,3])
C0001779 (UMLS CUI [2,4])
C0686906 (UMLS CUI [2,5])
C0018939 (UMLS CUI [2,6])
C5205410 (UMLS CUI [2,7])
Exclusion criteria: patients with M3 AML (Acute Promyelocytic Leukemia), patients who received treatments not including an anthracycline and cytosine arabinoside during induction treatment, patients who relapsed more than five years after the original diagnosis.
Item
Exclusion criteria: patients with M3 AML (Acute Promyelocytic Leukemia), patients who received treatments not including an anthracycline and cytosine arabinoside during induction treatment, patients who relapsed more than five years after the original diagnosis.
boolean
C0680251 (UMLS CUI [1,1])
C0023487 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,3])
C0282564 (UMLS CUI [1,4])
C0604937 (UMLS CUI [1,5])
C0857127 (UMLS CUI [1,6])
C0205336 (UMLS CUI [2,1])
C3843629 (UMLS CUI [2,2])
C0332137 (UMLS CUI [2,3])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video